Illumina Utdelningar och återköp
Utdelning kriterier kontrolleras 0/6
Illumina har inte registrerat sig för att betala utdelning.
Viktig information
n/a
Avkastning på utdelning
1.8%
Återköpsavkastning
| Total avkastning till aktieägarna | 1.8% |
| Framtida utdelningsavkastning | 0% |
| Utdelningstillväxt | n/a |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | n/a |
Senaste utdelnings- och återköpsuppdateringar
Inga uppdateringar
Recent updates
Seeking Alpha • Sep 08
Illumina: Priced For Perfection It Hasn't Earned Yet
Summary Illumina has surged 64% since my August 2024 Buy rating, driven by post-GRAIL spin-off momentum and operational discipline. ILMN's Q2 revenue grew 9.5% Y/Y to $1.16B, but organic growth was 6.5%; FCF margin declined to ~14% as FCF dropped to $162M. FY26 revenue guidance was raised to $4.60–$4.64B, implying 6–7% growth, but organic growth ex-currency and acquisitions is closer to 4%. Margin expansion is partly due to lumpy government incentives, not solely operational improvements; share buybacks paused amid liquidity management for upcoming $500M debt maturity. Read the full article on Seeking Alpha
Uppdatering av berättelse • Sep 07
ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Legal Setbacks
Analysts have lifted the Illumina fair value estimate from $172.53 to $199.63. They are factoring in a series of higher Street price targets tied to recent product pipeline updates, stronger Q2 execution, improving profit margin assumptions, and expectations for steadier long term instrument and consumables demand.
Uppdatering av berättelse • Aug 24
ILMN: Clinical Sequencing And Healthier Sector Spending Are Expected To Sustain A Balanced Outlook
Illumina's updated analyst price target moves to $230, supported by analysts citing stronger recent instrument placements, Q2 results that were generally viewed as solid, and expectations for healthier genomics and diagnostics spending over the coming years. Analyst Commentary Recent research on Illumina points to a more constructive tone from several bullish analysts who have raised price targets following Q2 results, updated guidance, and industry checks.
Uppdatering av berättelse • Aug 10
ILMN: Strong Clinical Sequencing Trends Will Likely Fail To Offset Execution Risks
Illumina's updated fair value estimate rises from $87.05 to $126.91 as analysts lift price targets across the sector, citing stronger Q2 results, solid instrument placements that may support consumables usage, and improving sentiment around clinical sequencing and long term growth initiatives. Analyst Commentary Recent research coverage on Illumina points to a clear reset higher in price targets across much of Wall Street.Uppdatering av berättelse • Jul 27
ILMN: Future Returns Will Depend On Clinical Sequencing Momentum Facing Legal Headwinds
The updated analyst price target for Illumina rises from about $147 to roughly $173 per share. This reflects analysts' use of higher sector multiples, modestly adjusted growth and profitability assumptions, and a generally more constructive view on diagnostics, genomics infrastructure, and AI supported research demand.Uppdatering av berättelse • Jul 13
ILMN: Clinical Sequencing Momentum And Sector Funding Support A Fairly Balanced Outlook
The fair value estimate for Illumina has been raised from $185 to $200, reflecting analysts' higher $200 price targets and their view that the company remains a core genomics infrastructure provider, as sector research points to healthy demand trends and solid customer engagement. Analyst Commentary Recent Street research on Illumina points to an increasingly constructive stance from several bullish analysts, with multiple firms revisiting assumptions on demand, execution, and the role of the company in genomics and broader life sciences tools.Uppdatering av berättelse • Jun 29
ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook
The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.Uppdatering av berättelse • Jun 15
ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness
Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.Uppdatering av berättelse • Jun 01
ILMN: Clinical Momentum And Softer Competition Will Shape A Balanced Outlook
Analysts have lifted the fair value estimate for Illumina from $156.51 to $175.00, citing Street research that points to building clinical momentum, easing competitive concerns, and a series of higher price targets from several firms. Analyst Commentary Recent Street research on Illumina has tilted more constructive, with several bullish analysts pointing to improving clinical traction and a less intense competitive backdrop as key supports for the stock.Analysartikel • May 11
We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings
Unsurprisingly, Illumina, Inc.'s ( NASDAQ:ILMN ) stock price was strong on the back of its healthy earnings report. We...Uppdatering av berättelse • Apr 30
ILMN: Policy And Execution Risks Will Likely Outweigh Supportive Genome Consumable Pricing
Illumina's analyst-derived fair value has shifted modestly lower from $88.35 to $87.05 as analysts balance mixed target changes and view Roche's less aggressive genome pricing as a near term positive that supports assumptions for slightly stronger revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Street research around Illumina reflects a mix of views, with some analysts highlighting potential upside from competitive pricing developments and others trimming price targets in response to ongoing execution and valuation questions.Uppdatering av berättelse • Apr 15
ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand
Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement. Analyst Commentary Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility.Uppdatering av berättelse • Apr 01
ILMN: Future Returns Will Depend On 2026 Tools Demand And Competitive Pricing
Illumina's analyst price target nudged up to about $136, as analysts point to slightly firmer revenue growth assumptions, a steady profit margin outlook, and supportive read-through from recent Street research, including Roche's less aggressive genome pricing. Analyst Commentary Street research around Illumina has turned more active, with several firms adjusting price targets and updating views on genomics demand and competitive risks.Uppdatering av berättelse • Mar 18
ILMN: Future Returns Will Hinge On China Recovery And 2026 Tools Demand
Illumina's updated analyst price target sits slightly higher at about $136, with analysts citing firmer revenue and margin assumptions, a modestly higher discount rate, and supportive recent commentary on competitive pricing for whole genome sequencing consumables. Analyst Commentary Recent Street research on Illumina reflects a mix of optimism and caution, with several firms adjusting price targets and reassessing the setup for the next couple of years.Uppdatering av berättelse • Mar 04
ILMN: Policy And Execution Risks Will Likely Limit Benefits From Supportive Consumables Pricing
Illumina's analyst price targets have seen a modest upward reset, with a slightly higher fair value estimate of $88.35. This is supported by Street research that highlights firmer competitive pricing in sequencing consumables and a range of recent target revisions tied to updated views on growth, margins, discount rates, and future P/E assumptions.Uppdatering av berättelse • Feb 18
ILMN: Policy And Execution Risks Will Likely Restrain Tools Thesis Upside
Illumina's updated analyst price target has increased to $87.97 from $80.00. This reflects analysts' mixed but generally more constructive views as they adjust for revised revenue growth, profit margin and future P/E assumptions following a series of recent target changes across the Street.Uppdatering av berättelse • Feb 03
ILMN: Future Returns Will Depend On China Access And 2026 Execution
Narrative Update: Illumina Analyst Target Shift Our Analyst Price Target for Illumina moves modestly higher by about $4 per share as analysts cite updated views on revenue growth, profit margins, and future P/E multiples following a series of recent price target increases across the Street. Analyst Commentary Bullish and cautious voices are both weighing in on Illumina, and most of the recent activity centers on refreshed views for 2026, broader life science tools demand, and where valuation might settle after recent share moves.Uppdatering av berättelse • Jan 20
ILMN: Future Returns Will Depend On China Recovery And Execution Through 2026
Analysts have raised their implied fair value for Illumina by about $12 to approximately $132 per share, reflecting updated views on revenue growth, profit margins and future P/E multiples, supported by a series of recent price target increases across the Street. Analyst Commentary Recent research updates cluster around higher price targets and mixed views on how reliably Illumina can deliver against those expectations.Uppdatering av berättelse • Jan 06
ILMN: China Export Restrictions Will Likely Cap Upside Despite Cost Efficiencies
Analysts have raised their price targets on Illumina to a range of roughly $100 to $195, citing recovering end markets, healthier procedure and CapEx trends into 2026, and cost efficiencies highlighted in recent quarterly results, even as they continue to flag limited visibility and ongoing challenges in China. Analyst Commentary Recent research updates present a mixed picture for Illumina, with higher price targets sitting alongside ongoing questions around visibility, execution, and regional headwinds.Uppdatering av berättelse • Dec 14
ILMN: China Export Risks Will Likely Limit Upside Despite Recent Optimism
Analysts raised our implied fair value estimate for Illumina by 7 dollars to 80 dollars per share. This reflects higher revenue growth and profit margin expectations following better than anticipated quarterly results and a series of upward price target revisions across the Street, despite lingering visibility concerns.Uppdatering av berättelse • Nov 30
ILMN: Future Performance Will Rely On China Market and Operational Execution
Analysts have modestly increased their price targets for Illumina, with the fair value estimate rising by $2.11 per share to $119.84. This reflects confidence in the company’s recent quarterly performance and operational improvements despite ongoing sector headwinds.Uppdatering av berättelse • Nov 16
ILMN: Future Momentum Will Depend On China Recovery And Efficiency Gains
Analysts have modestly raised their price target on Illumina, increasing fair value estimates from approximately $113.58 to $117.74. This reflects improved revenue growth and operational efficiency, despite mixed business visibility and regional challenges.Analysartikel • Nov 09
Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
The Illumina, Inc. ( NASDAQ:ILMN ) share price has done very well over the last month, posting an excellent gain of...Uppdatering av berättelse • Nov 01
ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties
Illumina's analyst price target has increased modestly, with the average rising from $111.95 to $113.58. Analysts cite stronger operational performance and revenue growth, even as the company faces ongoing sector and regional challenges.Uppdatering av berättelse • Sep 04
Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks
Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.Stabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Otillräcklig data för att avgöra om ILMN s utdelningar per aktie har varit stabila tidigare.
Växande utdelning: Otillräcklig data för att avgöra om ILMN s utdelningsbetalningar har ökat.
Utdelningsavkastning jämfört med marknaden
| Illumina Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (ILMN) | n/a |
| Marknadens lägsta 25% (US) | 1.4% |
| Marknad Topp 25% (US) | 4.1% |
| Genomsnitt för branschen (Life Sciences) | 0.6% |
| Prognosanalytiker (ILMN) (upp till 3 år) | 0% |
Anmärkningsvärd utdelning: Det går inte att utvärdera ILMN s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Hög utdelning: Det går inte att utvärdera ILMN s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Vinstutdelning till aktieägarna
Resultattäckning: Otillräcklig data för att beräkna ILMN s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom ILMN inte har rapporterat några utbetalningar.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/14 18:11 |
| Aktiekurs vid dagens slut | 2026/09/14 00:00 |
| Intäkter | 2026/06/28 |
| Årlig intjäning | 2025/12/28 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Illumina, Inc. bevakas av 48 analytiker. 19 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |